We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.50 | 8.89% | 6.125 | 6.00 | 6.25 | 7.25 | 5.125 | 5.625 | 5,461,200 | 16:26:13 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -1.37 | 7.05M |
From Apr 2019 to Apr 2024
TIDMGDR
RNS Number : 2703V
Genedrive PLC
05 April 2019
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has granted share options ("Options") to members of its senior management team to acquire a total of 1,330,000 ordinary shares of 1.5p each in the capital of the Company under the Company's Share Option Scheme.
The Options have been granted with an exercise price equal to the close price on the day before grant and vest after a period of three years. The Options are exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
Hot Features
Premium
1. Details of the person discharging managerial responsibilities
/ person closely associated
a. Name David Budd CEO
Matthew Fowler CFO
Gino Miele R&D Director
Gordon Powell Commercial Director
Colleen Pythian Director of Quality & Regulation
Warren Berry Operations Director
------------------------------- -------------------------------------------------------------
2. Reason for the notification
----------------------------------------------------------------------------------------------
a. Position/status 1.
------------------------------- -------------------------------------------------------------
a. Initial notification Initial notification
/Amendment
------------------------------- -------------------------------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
----------------------------------------------------------------------------------------------
a. Name genedrive plc
------------------------------- -------------------------------------------------------------
b. LEI
213800ZYODIRZ87Y4K14
------------------------------- -------------------------------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
----------------------------------------------------------------------------------------------
a. Description of Options over ordinary shares of 1.5 pence
the each
Financial instrument,
type
of instrument
Identification
code
------------------------------- -------------------------------------------------------------
b. Nature of the Grant of options pursuant to and in accordance
transaction with the terms of the Company's Share Option
Scheme dated 29 November 2017.
------------------------------- -------------------------------------------------------------
c. Price(s) and Option price(s) Volume(s)
volume(s) David Budd 23.5p 540,000
---------------- ----------
Matthew Fowler 23.5p 340,000
---------------- ----------
Gino Miele 23.5p 150,000
---------------- ----------
Gordon Powell 23.5p 150,000
---------------- ----------
Colleen Pythian 23.5p 75,000
---------------- ----------
Warren Berry 23.5p 75,000
---------------- ----------
------------------------------- -------------------------------------------------------------
d. Aggregated information
* Aggregated volume N/A
* Price
------------------------------- -------------------------------------------------------------
e. Date of the transaction 2019-April-04; UTC time
------------------------------- -------------------------------------------------------------
f. Place of the Outside trading venue - shares to be admitted
transaction to AIM market of London Stock Exchange plc
on exercise of options
------------------------------- -------------------------------------------------------------
For further details please contact:
genedrive plc +44 (0)161 989 0245 David Budd: CEO Matthew Fowler: CFO Peel Hunt LLP +44 (0)207 418 8900 James Steel / Oliver Jackson Stanford Capital Partners Limited +44 (0) 20 3815 8880 Patrick Claridge / John Howes Walbrook PR Ltd (Media Relations & Investor +44 (0)20 7933 8780 Relations) or genedrive@walbrookpr.com Paul McManus / Anna Dunphy
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DSHEAXLSEAPNEEF
(END) Dow Jones Newswires
April 05, 2019 03:29 ET (07:29 GMT)
1 Year Genedrive Chart |
1 Month Genedrive Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
